Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
2027. márc. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
2027. jan. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
2026. nov. 3.· JCO precision oncology· PUBMED
Publikáció
Case Report: Isolated leptomeningeal relapse after systemic control in PALB2-altered pancreatic cancer.
2026. okt. 12.· Frontiers in medicine· PUBMED
Publikáció
A Heterogeneous Phenotypic Presentation of a PALB2 Mutation Carrier With Multiple Metachronous Primary Malignancies: A Case Report.
2026. aug. 31.· Cureus· PUBMED
Publikáció
Age-Specific Ovarian Cancer Risk Among Individuals With Pathogenic Variants in PALB2.
2026. aug. 26.· JCO precision oncology· PUBMED
Publikáció
Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report.
2026. aug. 21.· Medicine· PUBMED
Publikáció
Germline PALB2 Genetic Variant Associated with Rapid Metastatic Progression and Poor Survival in Two Kazakh Women with Breast Cancer: A Case Study.
2026. júl. 31.· Genes· PUBMED
Publikáció
Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.
2026. jún. 1.· JAMA oncology· PUBMED
Publikáció
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
2026. máj. 1.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Investigating the contribution of rare non-coding variants in BRCA1, BRCA2 and PALB2 to hereditary breast cancer.
2026. ápr. 4.· NPJ breast cancer· PUBMED
Publikáció
High Prevalence of Non-BRCA Pathogenic Variants and a Recurrent PALB2 Variant in an Argentine Hereditary Breast and Ovarian Cancer Cohort.
2026. ápr. 1.· Cancer medicine· PUBMED
Publikáció
Unique social, identity, and community factors impact prophylactic surgery discussions in young adults who are BRCA1, BRCA2, and PALB2 positive.
2026. ápr. 1.· Journal of genetic counseling· PUBMED
Publikáció
A comprehensive and accessible model for co-segregation analysis in BRCA1, BRCA2, and PALB2 variant classification.
2026. márc. 26.· Human genetics· PUBMED
Publikáció
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada.
2026. márc. 11.· Annals of surgical oncology· PUBMED
Publikáció
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.
2026. febr. 16.· Breast (Edinburgh, Scotland)· PUBMED
Publikáció
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
2026. jan. 28.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma.
2026. jan. 18.· Pediatric blood & cancer· PUBMED
Publikáció
Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield.
2026. jan. 3.· Human mutation· PUBMED
Vizsgálat
Population Based Germline Testing for Early Detection and Prevention of Cancer
2025. dec. 18.· NA · RECRUITING· CTGOV
Publikáció
Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM).
2025. okt. 31.· JCO oncology advances· PUBMED
Vizsgálat
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
2025. jún. 10.· PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING· CTGOV
Vizsgálat
COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND A DELETERIOUS GERMLINE MUTATION IN BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 OR A HOMOLOGOUS RECOMBINATION DEFICIENCY
2024. nov. 28.· PHASE2 · COMPLETED· CTIS
Vizsgálat
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
2024. nov. 21.· PHASE1 · RECRUITING· CTGOV
Vizsgálat
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
2024. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV